Recombinant Newcastle disease virus expressing human interleukin-2 serves as a potential candidate for tumor therapy

Virus Research

Volumn 136, Issue 1-2, 2008, Pages 75-80

  Zhao, Heng ^a   Janke, Markus ^b   Fournier, Philippe ^b   Schirrmacher, Volker ^b  

^a CHINA AGRICULTURAL UNIVERSITY   (China)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Anti tumor; IL 2; Recombinant NDV

Indexed keywords

COMPLEMENTARY DNA; INTERLEUKIN 2; ONCOLYTIC ADENOVIRUS; RECOMBINANT PROTEIN; VIRUS RNA;

ANIMAL CELL; APOPTOSIS; ARTICLE; BIRD DISEASE; BODY TEMPERATURE; BREAST CARCINOMA; CANCER THERAPY; CELL PROLIFERATION; COLON ADENOCARCINOMA; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; INCUBATION TIME; MOLECULAR CLONING; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TEMPERATURE SENSITIVITY; VIROGENESIS;

CELL LINE, TUMOR; HUMANS; INTERLEUKIN-2; NEOPLASMS; NEWCASTLE DISEASE VIRUS; ONCOLYTIC VIRUSES;

NEWCASTLE DISEASE VIRUS;

EID: 46049109297     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virusres.2008.04.020     Document Type: Article

References (33)

1. Bukreyev A., Whitehead S.S., Bukreyeva N., Murphy B.R., and Collins P.L. Effect of coexpression of interleukin-2 by recombinant respiratory syncytial virus on virus replication, immunogenicity and production of other cytokines. J. Virol. 74 15 (2000) 7151-7157
2. Cassel W.A., and Garrett R.E. Newcastle disease virus as an antineoplastic agent. Cancer 18 (1965) 863-868
3. Cassel W.A., Murray D.R., and Phillips H.S. A phase II study on the postsurgical management of stage II malignant melanoma with a Newcastle disease virus oncolysate. Cancer 52 (1983) 856-860
4. Collins P.L., McIntosh K., and Chanock R.M. Respiratory syncytial virus. In: Fields B.N., Knipe D.M., and Howley P.M. (Eds). Virology. 3rd ed. (1996), Raven Press, New York, NY 1313-1351
5. Csatary L.K. Viruses in the treatment of cancer. Lancet ii (1971) 825
6. Csatary L.K., Gosztonyi G., Szeberenyi J., Fabian Z., Liszka V., Bodey B., and Csatary C.M. MTH-68/H oncolytic viral treatment in human high-grade gliomas. J. Neurooncol. 67 (2004) 83-93
7. Csatary L.K., Moss R.W., Beuth J., Torocsik B., Szeberenyi J., and Bakacs T. Beneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine (MTH-68/H). Anticancer Res. 19 (1999) 635-638
8. Elankumaran S., Rockemann D., and Samal S.K. Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death. J. Virol. 80 (2006) 7522-7534
9. Emerson S.U. Reconstitution studies detect a single polymerase entry site on the vesicular stomatitis virus genome. Cell 31 (1982) 635-642
10. Fábián Z., Torocsik B., Kiss K., Csatary L.K., Bodey B., Tigyi J., Csatary C., and Szeberenyi J. Induction of apoptosis by a Newcastle disease virus vaccine (MTH-68/H) in PC12 rat phaeochromocytoma cells. Anticancer Res. 21 (2001) 125-135
11. Fábián Z., Csatary C.M., Szeberenyi J., and Csatary L. p53-indenpendent endoplasmic reticulum stress-mediated cytotoxicity of a Newcastle disease virus strain in tumor cell lines. J. Virol. 81 (2007) 2817-2830
12. Fábián Z., Vecsernyes M., Pap M., and Szeberenyi J. The effects of a mutant p53 protein on the proliferation and differentiation of PC12 rat phaeochromocytoma cells. J. Cell. Biochem. 99 (2006) 1431-1441
13. Gaffen S.L., Goldsmith M.A., and Greene W.C. Interleukin-2 and Interleukin-2 Receptor (1998), Academic Press, San Diego, CA
14. Hu J.C., Coffin R.S., and Davis C.J. A phase I study of oncoVEX GM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin. Cancer Res. 12 (2006) 6737-6747
15. Janke M., Peeters B., de Leeuw O., Moorman R., Arnold A., Fournier P., and Schirrmacher V. Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy. Gene Ther. 10 (2007) 1-11
16. Krauzewicz N., and Griffin B.E. Polyoma and papilloma virus vectors for cancer gene therapy. Adv. Exp. Med. Biol. 4565 (2000) 73-82
17. Krishnamurthy S., Takimoto T., Scroggs R.A., and Portner A. Differentially regulated interferon response determined the outcome of Newcastle disease virus infection in normal and tumor cell lines. J. Virol. 80 (2006) 5145-5155
18. Krishnamurty S., and Samal S.K. Nucleotide sequence of the trailer, nucleocapsid protein gene and intergenic regions of Newcastle disease virus strain Beaudette C and completion of the entire genome sequence. J. Gen. Virol. 79 (1998) 2419-2424
19. Liebrich W., Schlag P., Manasterski M., Lehner B., Stohr M., Moller P., and Schirrmacher V. In vitro and clinical characterisation of a Newcastle disease virus-modified autologous tumour cell vaccine for treatment of colorectal cancer patients. Eur. J. Cancer 27 (1991) 703-710
20. Maas R.S., Dullens H.F., and Den Otter W. Interleukin-2 in cancer treatment: disappointment or (still) promising? A review. Cancer Immunol. Immunother. 33 (1993) 389-
21. Mayo M.A. A summary of taxonomic changes recently approved by ICTV. Arch. Virol. 147 (2002) 1655-1663
22. Miyahira Y., Garcia-Sastre A., Rodriguez D., Rodriguez J.R., Murata K., Tsuji M., Palese P., Esteban M., Zavala F., and Nussenzweg R.S. Recombinant viruses expressing human malaria antigen can elicit potentially protective immune CD8+ responses in mice. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 3954-3959
23. Mukherjees M.J., Haenel H.C., and Himbeck R. Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation. Cancer Gene Ther. 7 (2000) 663-670
24. Nicoletti I., Migliorati G., Pagliacci M.C., Grignani F., and Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods 139 (1991) 271-279
25. Parato K.A., Senger D., Forsyth P.A., and Bell J.C. Recent progress in the battle between oncolytic viruses and tumours. Nat. Rev. Cancer 5 (2005) 965-976
26. Phillips R.J., Samson A.C.R., and Emmerosn P.T. Nucleotide sequence of the 5′terminus of Newcastle disease virus and assembly of the complete genomic sequence: agreement with the "rule of six". Arch. Virol. 143 (1998) 1993-2002
27. Reichard K.W., Lorence R.M., Cascino C.J., Peeples M.E., Walter R.J., Fernando M.B., Reyes H.M., and Greager J.A. Newcastle disease virus selectively kills human tumor cells. J. Surg. Res. 52 (1992) 448-453
28. Schirrmacher V., and Haas C. Modification of cancer vaccines by virus infection and attachment of bispecific antibodies. An effective alternative to somatic gene therapy. Adv. Exp. Med. Biol. 451 (1998) 251-257
29. Schirrmacher V., Haas C., Bonifer R., Ahlert T., Gerhards R., and Ertel C. Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus. Gene Ther. 6 (1999) 63-73
30. Shah A.C., Benos D., Gillespie G.Y., and Markert J.M. Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas. J. Neuro-Oncol. 65 (2003) 203-226
31. Singh M., and Billeter M.A. A recombinant measles virus expressing biologically active human interleukin-12. J. Gen. Virol. 80 (1999) 101-106
32. Zhao H., and Peeters B.P.H. Recombinant Newcastle disease virus as a viral vector: effect of genomic location of foreign gene on gene expression and virus replication. J. Gen. Virol. 84 (2003) 781-788
33. Zorn U., Dallmann I., Grosse J., Kirchner H., Poliwoda H., and Atzpodien J. Induction of cytokines and cytotoxicity against tumor cells by Newcastle disease virus. Cancer Biother. 9 (1994) 225-235